Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

AMSTERDAM, The Netherlands, October 21, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time. The decision was made contrary to the positive recommendation of CHMP Rapporteurs, the Scientific Advisory Group (SAG), an expert panel specifically selected to evaluate clinical results and the science of the product, and the Committee for Advanced Therapies (CAT), which provides guidance on advanced therapeutics such as gene and cell therapy. These expert groups after extensive review and analysis of the data advised the CHMP that Glybera should be approved now under exceptional circumstances. The CHMP Rapporteurs, SAG and the CAT concluded that data from three Glybera clinical trials demonstrated meaningful evidence of clinical efficacy, without any major safety concerns. However, the CHMP is not bound to follow this advice. While AMT carefully reviews the grounds of the CHMP refusal, the Company will focus on strategic advancement of other promising projects in its development pipeline.

"The decision from the CHMP is disappointing particularly because a treatment will now not be available to European patients who suffer from LPLD for whom Glybera is the only therapeutic option. We are encouraged by the validation provided by the CHMP Rapporteurs, Scientific Advisory Group and the Committee for Advanced Therapies regarding our gene therapy platform, indicating that safety is not an issue," said Jörn Aldag, CEO of AMT. "We are evaluating thoroughly and expediently the next steps available to the Company and will provide an update on the future developments of our validated gene therapy pipeline."

On Tuesday October 25, 2011 at 10:00 AM CET, AMT will provide an update on
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ... navigate and understand both the current standard of care ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... whether technology developed to win races on the Formula ... obesity.  This unique healthcare collaboration between McLaren Applied Technologies ... academics at University Campus Suffolk is being funded by ... inspired by equipment used to collect data about the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS ... enhancement to its Online Web Portal for Life Science ... have the ability to specify the subject matter of ... 50 life science sub-domains. This will help reduce time-to-delivery ... scientific fields, and decrease the likelihood of error. , ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... ) in the Russian Federation ... members of the Commonwealth Independent States (CIS). Nemonoxacin is ... infections including those caused by drug-resistant bacteria. Under ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Minimally Invasive Treatment of Bone Fractures Achieves Significant ... Feb. 23 IlluminOss Medical Inc., a medical ... Stabilization System for orthopedic surgery, today announced that ... Registration issued by BSI (British Standards Institute). ...
... February 23 Health Robotics and Can-Med,today ... agreement whereby Can-Med,has acquired the exclusive distribution ... Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, Turkmenistan, Kyrgyzstan, ... only automated, point-of-care-distributed, and fail-safe,robotic system for ...
... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
Cached Biology Technology:IlluminOss Medical Receives ISO 13485 Certification 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3
(Date:4/15/2014)... LIVERMORE, Calif. Zero-emission hydrogen fuel cell systems soon could ... industrial settings at lower costs and with faster refueling ... Sandia National Laboratories and Hawaii Hydrogen Carriers (HHC). , ... solid-state hydrogen storage system that can refuel at low ... to charge a battery-powered forklift, giving hydrogen a competitive ...
(Date:4/15/2014)... research published in the March/April 2014 issue of ... shows whey protein, either as a supplement combined ... or weight-maintenance diet, may provide men and women benefits ... 14 randomized controlled trials with a total of 626 ... that used whey protein to replace calories in the ...
(Date:4/14/2014)... you,re over 24 years of age you,ve already reached ... according to a new Simon Fraser University study. ... professor Mark Blair, Thompson,s thesis supervisor, and Andrew Henrey, ... news in a just-published PLOS ONE Journal ... science experiments to rest on big data, the trio ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Study says we're over the hill at 24 2
... cells are the body,s mechanics, repairing damaged tissues and organs. ... of cell in the body, scientists believe they hold the ... scientists from the University of Victoria have found a new ... for regenerative medicine. "Cells in your body grow and ...
... Md. (March 1, 2012)The American Physiology Society (APS) has announced ... experimental animals and the sex or gender of humans used ... 13 peer-reviewed journals. This notable requirement for all research study ... be presented in an editorial, " In Pursuit of Scientific ...
... PULLMAN, Wash.A Washington State University researcher has demonstrated that a ... just an exposed animal but the next three generations of ... the compounds change the way genes turn on and offthe ... Skinner and expanded on in the current issue of the ...
Cached Biology News:APS issues new policy requiring identification of sex or gender in reporting scientific research 2APS issues new policy requiring identification of sex or gender in reporting scientific research 3Effects of environmental toxicants reach down through generations 2
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... Roche Applied Science, which pioneered the blending ... High Fidelity and Expand Long Template PCR ... PCR System the first product of ... This new blend combines Taq DNA Polymerase ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
Biology Products: